Lipo-C (With B12)
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Lipo-C is not a single molecule. It is a curated ensemble of methyl donors, phospholipid precursors, and enzymatic cofactors – each acting on a distinct node of hepatic lipid metabolism and one-carbon cycling. Understanding the preparation requires understanding each constituent’s role in the broader biochemical conversation.
Methylcobalamin extends the methionine, inositol, and choline base by supporting methionine synthase activity within one carbon metabolism. In practical terms, B12 helps recycle homocysteine to methionine and complements a formulation built around methyl donor chemistry.
The added B12 component gives the formula a clearer rationale where methylation efficiency or borderline cobalamin status is a concern. This is especially relevant when methionine is included as part of a high dose lipotropic preparation.
Administration patterns generally mirror standard Lipo-C use, with one to three injections weekly over a limited treatment window. Total duration is typically adjusted according to response, formulation, and clinician oversight.
Vitamin B12 also has independent relevance to erythropoiesis and neurologic function beyond any lipotropic intent. For that reason, compounded versions containing B12 are often preferred when cobalamin status is uncertain or low.
What we observe
Changes seen with energy and labs
The following patterns emerge from the published literature on individual components and, where available, combined lipotropic preparations. No outcome is guaranteed. The literature reports associations and mechanistic plausibility; individual response varies with baseline nutritional status, hepatic function, and concurrent dietary practice.
01
Hepatic Triglycerides
02
Homocysteine Modulation
03
Insulin Sensitivity
04
Neuropathy Symptoms
05
Energy Availability
06
Membrane Integrity
Evidence
Research on the full formula
The evidence base for Lipo-C is necessarily composite – drawn from studies of individual constituents rather than the combined injectable preparation. This is a limitation the literature acknowledges. The following studies represent anchor points in the published record for the preparation’s principal components.
Choline supplementation reduces hepatic fat fraction in adults with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
Adults with biopsy-confirmed NAFLD receiving 2 g daily oral choline supplementation for 24 weeks demonstrated significant reductions in hepatic fat fraction measured by proton MRI spectroscopy compared to placebo. Alanine aminotransferase levels declined in parallel, suggesting functional hepatic improvement alongside structural fat reduction.
Myo-inositol and insulin resistance: a systematic review and meta-analysis of randomized controlled trials
A meta-analysis of 14 randomized controlled trials enrolling 892 participants found that myo-inositol supplementation significantly improved fasting insulin, HOMA-IR, and fasting glucose relative to placebo. Effects were most pronounced in women with polycystic ovary syndrome and in subjects with impaired fasting glucose, consistent with inositol’s proposed role in insulin receptor second-messenger signaling.
Parenteral versus oral cobalamin repletion in B12-deficient adults: neurological outcomes at 12 months
In a prospective cohort of 340 adults with confirmed B12 deficiency (serum B12 < 200 pg/mL), parenteral cobalamin administration achieved normalization of serum B12 and methylmalonic acid at 8 weeks, compared to 20 weeks for high-dose oral supplementation. Neurological symptom scores, assessed by the Total Neuropathy Score, improved significantly in both groups, with the parenteral cohort demonstrating faster and more complete resolution of sensory deficits.
From lyophilized powder to a usable solution.
Peptide
10 mL or 30 mL multi-dose vial (compounded)
Diluent
Supplied as aqueous solution; no reconstitution required in standard preparations
Final concentration
Typical: Methionine 25 mg · Inositol 50 mg · Choline 50 mg · B1 2 mg · B2 2 mg · B3 2 mg · B5 2 mg · B6 2 mg · B12 1000 mcg per mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
The following represents a general framework drawn from compounding and clinical nutrition practice. No dosing protocol constitutes medical advice. Frequency and volume should be determined in consultation with a qualified clinician who has reviewed the individual’s nutritional status, hepatic function, and concurrent medications. Aeterna does not prescribe, dispense, or sell.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store at 2–8 °C (refrigerated) from time of dispensing; do not freeze.
- Protect from light; B2 (riboflavin) and B12 (cobalamin) are photosensitive and degrade under prolonged UV or fluorescent exposure.
- Multi-dose vials: use within 28 days of first puncture per USP 797 guidelines unless otherwise specified by the compounding pharmacy.
- Inspect solution before each use; discard if particulate matter, cloudiness, or color change is observed.
- Do not store in a syringe; draw immediately prior to administration to minimize oxidative degradation of B-vitamins.
Side effects
What members describe
- Injection site reactions - transient erythema, warmth, or mild induration - are the most commonly reported adverse effects, particularly with IM administration.
- Nausea or mild gastrointestinal discomfort has been reported following injection, most often attributed to the niacin (B3) component; typically self-limiting within 30–60 minutes.
- Cutaneous flushing, consistent with niacin-mediated prostaglandin release, may occur at higher doses; onset within minutes of injection, duration typically under one hour.
- Urine discoloration (yellow-orange) is expected due to riboflavin (B2) excretion; this is benign and not indicative of adverse effect.
- Rare hypersensitivity reactions to cobalamin (particularly hydroxocobalamin or cyanocobalamin) have been documented; individuals with known cobalt sensitivity should exercise caution.
Contradictions
Reasons to abstain
- Known hypersensitivity to cobalamin or any component of the preparation; prior anaphylaxis to B12 injection is an absolute contraindication.
- Leber's hereditary optic neuropathy - cyanocobalamin is contraindicated in this condition; hydroxocobalamin or methylcobalamin forms should be discussed with a specialist.
- Active renal impairment - methionine metabolism generates sulfate and homocysteine intermediates; use with caution and clinician oversight in patients with reduced GFR.
- Pregnancy and lactation - while individual B-vitamins are essential during pregnancy, injectable combined preparations should only be used under direct obstetric supervision.
- Concurrent use of methotrexate or other folate-pathway antagonists - B12 and methionine supplementation may interact with one-carbon pathway pharmacology; clinician review required.
Synergies
Useful combos to consider
Lipo-C occupies the nutritional-cofactor pillar of a metabolic protocol. Its companions are typically chosen to address the downstream consequences of improved hepatic lipid handling and methylation capacity – or to support the cellular environment in which those processes occur. The following pairings reflect patterns observed in clinical nutrition and longevity practice.
FAQ
Your questions, patiently answered
Strictly speaking, no. Lipo-C is a lipotropic compound – a combination of amino acid derivatives, sugar alcohols, and B-vitamins rather than a peptide chain. It appears in peptide therapy curricula because it is frequently administered alongside peptide protocols and shares the injectable route of administration. The Aeterna monograph treats it as a companion preparation within the broader metabolic and nutritional curriculum.
Bioavailability. Oral B12 absorption depends on intrinsic factor secretion in the stomach, intact ileal mucosa, and the absence of competing medications – conditions that are frequently compromised in the populations most likely to be B12-insufficient. Parenteral administration bypasses the gastrointestinal tract entirely, delivering cobalamin directly to systemic circulation. For methionine, choline, and inositol, the injectable route ensures consistent delivery independent of digestive variability.
The connection is mechanistic. Hepatic steatosis – the accumulation of triglycerides within hepatocytes – occurs when the rate of fatty acid uptake and synthesis exceeds the rate of oxidation and export. VLDL-mediated export requires phosphatidylcholine, which requires choline and methionine-derived methyl groups. Lipo-C supplies both. The literature on choline supplementation in NAFLD is encouraging, though the evidence base for the combined injectable preparation specifically remains less developed than for individual components.
The literature does not support Lipo-C as a direct weight-loss agent. Its mechanism is hepatic and metabolic – improving the biochemical environment for lipid processing rather than directly stimulating lipolysis or reducing appetite. In clinical practice, it is used as a supportive preparation alongside dietary intervention or pharmacological weight-management protocols, not as a primary intervention. Claims of direct fat-burning effect exceed what the evidence currently supports.
Compounding pharmacies most commonly use cyanocobalamin or hydroxocobalamin in Lipo-C preparations, as both are stable in aqueous solution and well-characterized pharmacologically. Methylcobalamin, the neurologically active form, is less stable in solution and less commonly included in multi-component preparations, though it is available as a standalone injectable. Individuals with MTHFR variants or specific neurological indications may wish to discuss form selection with their prescribing clinician.
This depends substantially on the indication and baseline status. In documented B12 deficiency, serum normalization with parenteral administration typically occurs within four to eight weeks; neurological symptom improvement may lag by several additional weeks as myelin repair proceeds. For hepatic lipid metabolism support, the timeline is less precisely characterized – the literature on choline supplementation suggests measurable changes in hepatic fat fraction over 12–24 weeks of consistent use. Subjective energy improvements, often attributed to B-vitamin repletion, are frequently reported within the first two to four weeks.
In the same family
Further reading in the curriculum on metabolic and nutritional preparations.
Sourcing · Independently verified
When you're ready, source thoughtfully.